Adalimumab Drug Optimisation in Rheumatoid Arthritis Using Therapeutic Drug Monitoring

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE4

Total Enrollment

267 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-03-01

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Several prior studies have shown that dose reduction of Tumor Necrosis Factor (TNF)-inhibitors like adalimumab is possible in substantial number of rheumatic disease patients without an increase in disease activity. Biologic therapy is expensive, and is associated with patient burden as dose dependant risk for serious infections . A dose reduction will decrease the risk of side effects and result in substantial cost savings. Currently, most clinicians use Disease Activity Score in 28 joints (DAS28) and the Clinical Disease Activity Index (CDAI) to monitor dose tapering strategies. Although this approach is cost-effective, it might be improved by information on the extent of drug levels, as several studies have shown that adalimumab drug levels are associated with clinical outcome. Therefore, a study comparing dose reduction strategy using drug concentration with dose reduction strategy using disease activity is timely

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Adalimumab Dose Reduction Aiming Low Serum Concentration With Control of Disease Activity

NCT04222920

Rheumatoid Arthritis

COMPLETED PHASE4

Using Adalimumab Serum Concentration to Choose a Subsequent Biological DMARD in Rheumatoid Arthritis Patients Failing Adalimumab Treatment

NCT04251741

Rheumatoid Arthritis

ACTIVE_NOT_RECRUITING PHASE4

Doppler Evaluation in RA Patients After Adalimumab.

NCT01609205

Rheumatoid Arthritis

COMPLETED PHASE4

Proactive Therapeutic Drug Monitoring Based Adalimumab Therapy Optimization in Patients With Rheumatoid Arthritis

NCT05460390

Rheumatoid Arthritis

TERMINATED NA

Efficacy and Safety of Adalimumab in Patients With Active Rheumatoid Arthritis Treated Concomitantly With Methotrexate.

NCT00195702

Rheumatoid Arthritis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Since the introduction of biologics in rheumatology, as well as treat-to-target (measuring disease activity and adapting treatment accordingly) the prognosis of patients has improved substantially. Obviously, patient burden due to self-injection or infusion, the risk of adverse events and costs demand responsible use of these agents. Multiple studies have shown that a large proportion of patients with rheumatoid arthritis with stable low disease activity can taper their dose or stop without relapse of disease activity. This can be done by using disease activity guided tapering. Drawbacks, however, include increased risk for short lived flares, the effort of slowly and carefully tapering, and somewhat more risk of radiographic damage due to higher mean disease activity. As most biologics are characterized by wide variation in pharmacokinetics between patients, therapeutic drug monitoring (TDM), i.e. dose based on serum trough concentration, might be an attractive approach to lower the dose quickly while remaining clinical efficacy. Although some data suggest that the minimal effective concentration varies between patients, we demonstrated in an earlier study that serum adalimumab concentration of 5 mg/L is enough for initial response to adalimumab. In the first phase of treatment, drug concentration must be high enough to control immunogenicity. To control disease activity after 28 weeks, lower concentrations than 5 mg/L are probably sufficient. Since around 70% of the patients have an adalimumab concentration above 5 mg/l, we assume that dose reduction to achieve these lower targets (for example direct doubling of interval in patients with levels \> 10 mg/L) will result in the lowest effective drug dose. Our study group illustrated in 2018 that dose reduction by extending the dosing interval with 50% is non inferior to continuation of standard dose in patients with adalimumab levels \> 8mg/L. In other words, measuring drug concentrations can help clinicians to select overexposed patients to reduce the dose of adalimumab without adversely affecting clinical efficiency. We posit that therapeutic drug monitoring can attribute to a more efficient dose reduction strategy. Since steady state drug concentrations are achieved within 16 weeks of treatment, we expect that the dose can be reduced from this point. This is earlier in treatment compared to the strategy using disease activity alone, namely after 6 months of treatment. Conceptually, such a test can improve disease activity guided dose reduction in two ways: 1) flaring caused by empirical tapering (i.e. through trial and error) below the minimal effective concentration would be avoided, and 2) patients can be directly given their minimum effective dose instead of empirical tapering, thereby saving time and drugs. Our aim is to investigate whether the use of drug levels can attribute to a more efficient dose reduction strategy of adalimumab in patients with RA. In this study we will compare costs and clinical efficiency of two dose reduction strategies: a strategy using drug concentration versus a strategy using disease activity scores. We expect that direct medical costs will be lower in the 'drug concentration guided' strategy because: 1) overexposed patient can reduce the dose more timely and, 2) adalimumab dose can be further reduced after 6 months of treatment since we posit that adalimumab concentration of 2 mg/L is sufficient to control disease.

In this multi-centre, randomised, open-label trail we will evaluate whether dose reduction of adalimumab using drug concentration can reduce medical costs compared to a strategy using disease activity scores. Furthermore we will evaluate the clinical efficiency of these two strategies.

Patients with a good or moderate EULAR response to adalimumab will be randomised to adalimumab dose reduction strategy using drug concentration or disease activity scores. Patients in the 'drug concentration guided' group will reduce adalimumab dose by prolonging the dose-interval using TDM algorithm (a new developed algorithm is used to determine the interval prolongation for each patient). The dose reduction will start at week 16 if trough drug level is higher than 5mg/L, aiming a drug level of 5mg/L in week 16 until 28 and a drug level of 2mg/L from week 28 until week 52. In the initial 16 weeks patients are treated with adalimumab at registered dose of 40mg every other week.

Patients in the 'disease activity guided' group will reduce adalimumab dose at week 28 if DAS28-CRP is lower than 2.9. This dose reduction will be attained by extending the dosing interval to every 3 weeks in weeks 28 until 40 and to every 4 weeks from week 40 until week 52.

Patients who successfully prolonged the dose interval to 40 mg every 4 weeks in the 'disease activity guided' group and patients who successfully prolonged their dose-interval and achieve a serum concentration of 2.0 mg/L in the 'drug concentration guided' group will be approached to participate to the extension phase (week 52-80). After informed consent is obtained patients will discontinue adalimumab and they will be followed up to week 80.

Data regarding disease status, functioning, adalimumab serum concentrations, anti-drug antibodies and medical costs will be collected during this study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rheumatoid Arthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Rheumatoid arthritis patients treated with adalimumab will be randomly assigned to a dose reduction strategy using disease activity scores or to a dose reduction strategy using serum drug concentrations

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

During every study visit the joints of all patients will be examined for pain and swelling by a blinded nurse or physician. The number of painful and swollen joints will be used to calculate the DAS28 score, the primary outcome of the study

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Concentration guided dose reducion

Dose reduction of adalimumab will be based on adalimumab through concentration after 16 weeks of treatment with adalimumab.

Group Type EXPERIMENTAL

Adalimumab serum trough concentration

Intervention Type DIAGNOSTIC_TEST

Dose reduction based on adalimumab serum trough concentration

Adalimumab

Intervention Type DRUG

Adalimumab

Disease activity quided dose reduction

Dose reduction of adalimumab will be based on disease activity after 28 weeks of treatment with adalimumab

Group Type ACTIVE_COMPARATOR

Disease activity

Intervention Type DIAGNOSTIC_TEST

Dose reduction based on adalimumab diseas activity

Adalimumab

Intervention Type DRUG

Adalimumab

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Adalimumab serum trough concentration

Dose reduction based on adalimumab serum trough concentration

Intervention Type DIAGNOSTIC_TEST

Disease activity

Dose reduction based on adalimumab diseas activity

Intervention Type DIAGNOSTIC_TEST

Adalimumab

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Rheumatoid arthritis patient, according to ACR 1987 or ACR/EULAR 2010 criteria;
* Starting adalimumab as the first biological therapy
* Who has agreed to participate (written informed consent);
* Age 18 years or older.

Exclusion Criteria

* Scheduled surgery during the follow-up of the study or other pre-planned reasons for treatment discontinuation;
* Life expectancy shorter than follow-up period of the study;
* Other disease that might flare if adalimumab is tapered like psoriasis, inflammatory bowel disease.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No